Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

abstract：:Two studies were carried out (A and B) in order to assess the effectiveness of ifosfamide administered with mesna (IFO/M) in the treatment of small cell lung cancer. The first study (A) was a cross-over study; the second (B) was a randomized trial, and in B IFO/M was evaluated earlier in the course of the disease. IFO...

journal_title：Cancer chemotherapy and pharmacology

authors： Cantwell BM,Harris AL,Bozzino JM

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor rec...

journal_title：Cancer chemotherapy and pharmacology

authors： Fukushima T,Wakatsuki Y,Kobayashi T,Sonehara K,Tateishi K,Yamamoto M,Masubuchi T,Yoshiike F,Hirai K,Hachiya T,Koizumi T

更新日期：2018-06-01 00:00:00

abstract：:Use of cross-sectional imaging to identify whole-body lean soft-tissue mass has recently emerged as an attractive prognostic factor for chemotherapy toxicities. Beyond that, there is increasing interest in use of lean soft-tissue mass as a more accurate method for dosing chemotherapy, as compared to body surface area....

journal_title：Cancer chemotherapy and pharmacology

authors： Hopkins JJ,Sawyer MB

更新日期：2018-07-01 00:00:00

abstract：PURPOSE:The survival benefit of chemotherapy (CTx) compared with best supportive care (BSC) is unclear in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC) previously treated with fluorouracil (FU), platinum (PT), and taxane (TAX). PATIENTS AND METHODS:The data of 283 consecutive pati...

journal_title：Cancer chemotherapy and pharmacology

authors： Nomura M,Iwasa S,Tsushima T,Kato K,Yasui H,Boku N,Muto M,Muro K

更新日期：2016-12-01 00:00:00

abstract：:Previous studies have demonstrated that treatment with fludarabine 4 h prior to arabinosylcytosine (ara-C) potentiates the accumulation of the active triphosphate of ara-C (ara-CTP) in leukemic lymphocytes. The clinical efficacy of this combination was evaluated in 15 patients with chronic lymphocytic leukemia (CLL) t...

journal_title：Cancer chemotherapy and pharmacology

authors： Gandhi V,Robertson LE,Keating MJ,Plunkett W

更新日期：1994-01-01 00:00:00

abstract：BACKGROUND:Very little is known about the pharmacokinetics of chemotherapeutic agents in patients also being treated with continuous ambulatory peritoneal dialysis. We sought to evaluate the pharmacokinetics of cisplatin and 5-fluorouracil in plasma and peritoneal dialysate in a patient being treated for esophageal ade...

journal_title：Cancer chemotherapy and pharmacology

authors： Eads JR,Beumer JH,Negrea L,Holleran JL,Strychor S,Meropol NJ

更新日期：2016-02-01 00:00:00

abstract：:Dose fractionation is known to reduce the toxicity of ifosfamide and also results in an increased production of alkylating metabolites. Administration by slow infusion using the convenience of ambulatory pumps is therefore of interest. We used HPLC to investigate the stability of ifosfamide in aqueous solution (either...

journal_title：Cancer chemotherapy and pharmacology

authors： Radford JA,Margison JM,Swindell R,Lind MJ,Wilkinson PM,Thatcher N

更新日期：1990-01-01 00:00:00

abstract：:The cytotoxic action of 5-aza-2'-deoxycytidine (5-AZA-CdR) in synchronized cells and logarithmic- and plateau-phase cultures of EMT6 murine tumor cells was investigated. 5-AZA-CdR produced a greater cell kill of S phase cells than of cells in G1 phase. Cells in the logarithmic phase of growth were more sensitive to th...

journal_title：Cancer chemotherapy and pharmacology

authors： Momparler RL,Samson J,Momparler LF,Rivard GE

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:Clinical data suggested that a regimen incorporating doxorubicin to 5-fluorouracil (5-FU) and cisplatin may be more effective but probably quite toxic for advanced gastric cancer patients. With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, ci...

journal_title：Cancer chemotherapy and pharmacology

authors： Cascinu S,Galizia E,Labianca R,Ferraù F,Pucci F,Silva RR,Luppi G,Beretta GD,Berardi R,Scartozzi M

更新日期：2011-07-01 00:00:00

abstract：:Both the capacity of healthy human, cancer patient, and mouse plasma proteins to bind flavone acetic acid (FAA) and the qualitative differences in the plasma protein-binding site were studied. The binding capacity of plasma proteins for FAA was saturated within the therapeutic range in both species. The binding of FAA...

journal_title：Cancer chemotherapy and pharmacology

authors： Brodfuehrer J,Valeriote F,Chan K,Heilbrun L,Corbett T

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as...

journal_title：Cancer chemotherapy and pharmacology

authors： Amato R,Stepankiw M,Gonzales P

更新日期：2013-06-01 00:00:00

abstract：:Nanoparticulate carriers of anthracyclines are being developed with the aim of improving the pharmacokinetic or pharmacodynamic behavior of these drugs. To understand how the drug reaches its nuclear targets, we have developed two methods that allow the quantification of the interaction between an anthracycline and ce...

journal_title：Cancer chemotherapy and pharmacology

authors： Bogush T,Smirnova G,Shubina I,Syrkin A,Robert J

更新日期：1995-01-01 00:00:00

abstract：BACKGROUND:Fenretinide is a synthetic retinoid that can induce cytotoxicity by several mechanisms. Achieving effective systemic exposure with oral formulations has been challenging. An intravenous lipid emulsion fenretinide formulation was developed to overcome this barrier. We conducted a study to establish the maximu...

journal_title：Cancer chemotherapy and pharmacology

authors： Thomas JS,El-Khoueiry AB,Maurer BJ,Groshen S,Pinski JK,Cobos E,Gandara DR,Lenz HJ,Kang MH,Reynolds CP,Newman EM

更新日期：2021-01-10 00:00:00

abstract：PURPOSE:To investigate the antitumor effects of tyroserleutide (tyrosyl-seryl-leucine, YSL) on human Bel7402 hepatocarcinoma in vitro and in vivo, with preliminary exploration of its antitumor mechanism. METHODS:MTT was used to observe the anticarcinogenic effects of YSL on human hepatocarcinoma Bel7402 cells in vitro...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu R,Jia J,Bao L,Fu Z,Li G,Wang S,Wang Z,Jin M,Gao W,Yao Z

更新日期：2006-01-01 00:00:00

abstract：:Valinomycin is a depsipeptide antibiotic that selectively translocates potassium ion across biologic membranes. This drug has been reported to display antitumor effects, but its use has been limited by its extreme toxicity. However, its incorporation into lipid vesicles (liposomes) has resulted in a reduction in toxic...

journal_title：Cancer chemotherapy and pharmacology

authors： Daoud SS,Juliano RL

更新日期：1989-01-01 00:00:00

abstract：:This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamethasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alon...

journal_title：Cancer chemotherapy and pharmacology

authors： Frustaci S,Grattoni E,Tumolo S,Crivellari D,Figoli F,Galligioni E,Veronesi A,Tirelli U,Grigoletto E

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:This study aimed to compare the survival of patients enrolled in phase 1 trials in recent decades. METHODS:The medical records of consecutive patients with advanced cancer who participated in single-agent oncology phase 1 trials from 1995 to 2015 at a single institution were retrospectively investigated. RESU...

journal_title：Cancer chemotherapy and pharmacology

authors： Ebata T,Shimizu T,Koyama T,Shimomura A,Iwasa S,Kondo S,Kitano S,Yonemori K,Fujiwara Y,Yamamoto N

更新日期：2020-02-01 00:00:00

abstract：INTRODUCTION:Hormone-refractory disseminated prostate cancer is a major oncological problem. Preclinical studies with temozolomide, an oral alkylating agent, in prostate cancer have shown encouraging results. In phase I studies the safety of temozolomide in non-prostate cancer patients has been demonstrated. Based on t...

journal_title：Cancer chemotherapy and pharmacology

authors： van Brussel JP,Busstra MB,Lang MS,Catsburg T,Schröder FH,Mickisch GH

更新日期：2000-01-01 00:00:00

abstract：:Brain microdialysis was applied to sample free methotrexate (MTX) concentrations in brain extracellular fluid of normal and RG-2 glioma-bearing rats. All animals received 50 mg/kg of MTX intra-arterially following which serial blood and interstitial fluid samples were collected for 3 h and measured for MTX by an HPLC ...

journal_title：Cancer chemotherapy and pharmacology

authors： Devineni D,Klein-Szanto A,Gallo JM

更新日期：1996-01-01 00:00:00

abstract：BACKGROUND:Statins have potential antineoplastic properties via arrest of cell-cycle progression and induction of apoptosis. A previous study demonstrated in vitro and in vivo antineoplastic synergism between statins and gemcitabine. The present randomized, double-blinded, phase II trial compared the efficacy and safet...

journal_title：Cancer chemotherapy and pharmacology

authors： Hong JY,Nam EM,Lee J,Park JO,Lee SC,Song SY,Choi SH,Heo JS,Park SH,Lim HY,Kang WK,Park YS

更新日期：2014-01-01 00:00:00

abstract：PURPOSE:The combination of capecitabine and paclitaxel (XP) has demonstrated synergistic antitumor activity in preclinical models. The purpose of this phase II study was to evaluate the efficacy and safety of a monthly XP regimen in patients with metastatic breast cancer (MBC). METHODS:Eligible patients had received o...

journal_title：Cancer chemotherapy and pharmacology

authors： Taguchi T,Yamamoto D,Masuda N,Oba K,Nakayama T,Nagata T,Nomura M,Yoshidome K,Yoshino H,Matsunami N,Miyashita M,Furuya Y,Ishida T,Wakita K,Sakamoto J,Noguchi S,Kinki Breast Cancer Study Group (KBCSG).

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:Cetuximab and panitumumab are chimeric and fully human monoclonal antibodies, respectively, against epidermal growth factor receptor used in the treatment of metastatic colorectal cancer (mCRC). Incidence of documented infusion reaction (IR) is more common with cetuximab (all grades [g]: 15-21%, g 3/4: 2-5%)...

journal_title：Cancer chemotherapy and pharmacology

authors： Saif MW,Syrigos KI,Hotchkiss S,Shanley J,Grasso J,Ferencz TM,Syrigos K,Shah MM

更新日期：2009-12-01 00:00:00

abstract：:Etoposide is a widely used cytotoxic drug that requires complex formulation for both the i.v. and oral preparation to ensure drug stability. Data on the stability of the i.v. formulation when diluted in infusion fluids are contradictory, and there is little information on the stability of the oral preparation in gastr...

journal_title：Cancer chemotherapy and pharmacology

authors： Joel SP,Clark PI,Slevin ML

更新日期：1995-01-01 00:00:00

abstract：:Cyclophosphamide demonstrates enhanced tumoricidal activity with decreased bone marrow toxicity when given on a divided-dose schedule in certain animal models. A total of 22 patients presenting with refractory metastatic cancer were treated in a phase I trial of continuous infusion of cyclophosphamide over 96 h. Granu...

journal_title：Cancer chemotherapy and pharmacology

authors： Eder JP,Elias AD,Ayash L,Wheeler CA,Shea TC,Schnipper LE,Frei E 3rd,Antman KH

更新日期：1991-01-01 00:00:00

abstract：:We have recently demonstrated that continuous-infusion (CI) 5-fluorouracil (FU) eradicates human colon carcinoma cells made resistant to bolus FU in vitro. In addition, in the same experimental system, the mechanisms of resistance to pulse and CI FU were found to be different. These observations led us to test the cli...

journal_title：Cancer chemotherapy and pharmacology

authors： Mori A,Bertoglio S,Guglielmi A,Aschele C,Bolli E,Tixi L,Rosso R,Sobrero A

更新日期：1993-01-01 00:00:00

abstract：:Pegylated liposomes have been studied for nearly two decades. However, fewer pharmacological studies about its application in daunorubicin (DNR) than those in doxorubicin have been reported. In order to conduct a complete pharmacokinetic study, radiolabeled DNR was encapsulated in pegylated liposomes. Its in vitro dru...

journal_title：Cancer chemotherapy and pharmacology

authors： Song H,Zhang J,Han Z,Zhang X,Li Z,Zhang L,Fu M,Lin C,Ma J

更新日期：2006-05-01 00:00:00

abstract：PURPOSE:To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:A group of 38 patients with advanced or metastatic NSCLC who had not rece...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsunoda T,Koizumi T,Hayasaka M,Hirai K,Koyama S,Takabayashi Y,Fujimoto K,Kubo K

更新日期：2004-08-01 00:00:00

abstract：:The acute and chronic cardiotoxicity and cytotoxicity of the novel doxorubicin (DXR) derivative 4'-amino-3'-hydroxy-DXR were compared with those of 4'-deoxy-DXR and DXR. In the acute cardiotoxicity study, the ECG and hemodynamic changes recorded in anesthetized rats that had been treated i.v. with 10 mg/kg 4'-amino-3'...

journal_title：Cancer chemotherapy and pharmacology

authors： Danesi R,Bernardini N,Agen C,Costa M,Zaccaro L,Pieracci D,Malvaldi G,Del Tacca M

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. METHODS:Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10...

journal_title：Cancer chemotherapy and pharmacology

authors： Friedman HS,Keir ST,Houghton PJ,Lawless AA,Bigner DD,Waters SJ

更新日期：2001-11-01 00:00:00

abstract：BACKGROUND:The presence of hepatic portal venous gas (HPVG) is a rare finding. It is most commonly caused by bowel necrosis and typically carries a grave prognosis. Bevacizumab has emerged as an effective standard therapy in the frontline management of advanced non-small cell lung cancer (NSCLC). Although bevacizumab i...

journal_title：Cancer chemotherapy and pharmacology

authors： Ortega J,Hayes JM,Antonia S

更新日期：2009-12-01 00:00:00